- Cello Health said it had acquired Innovative Science Solutions for up to $10.5m.

Under the terms of the deal, Cello paid an initial consideration of $6.4m in cash and agreed to pay a deferred consideration of up to $4.1m in four tranches, each dependent on the financial performance of Science Solutions over the periods from 1 August 2019 to 31 July 2024. This deferred consideration would be paid in a minimum of 80% cash, with the balance to be satisfied through the issue of new ordinary shares in Cello. For the year to 31 December 2018, ISS had an unaudited revenue of $5.0m, net revenue of $4.5m, unadjusted profit before tax of $2.8m and adjusted operating profit of $1.8m. 'The acquisition of ISS reflects Cello's strategy of expanding further in the US and adds a key incremental component to Cello's offering of technical services along critical drug development pathways. It is anticipated that there will be strong mutual client opportunity over time,' the company said.

Story provided by